Article
Prediction of immunotherapy response using deep learning of PET/CT images
2020-10-11
Abstract excerpt
Currently only a fraction of patients with non-small cell lung cancer (NSCLC) experience durable clinical benefit (DCB) from immunotherapy, robust biomarkers to predict response prior to initiation of therapy are an emerging clinical need. PD-L1 expression status from immunohistochemistry is the only clinically approved biomarker, but a non-invasive complimentary approach that could be used when tissues are not av...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cb55fcbd-9d68-5e14-8dda-c34c4bd74a46
- DOI
- 10.1101/2020.10.09.20209445
